This trial is concluded. This means the trial has been completed. When the results of the trial have been made public, they will be summarised in the 'outcomes' section of this page. You cannot enrol in this trial.
This is a retrospective review of people who have tried a combination including a non-nucleoside reverse transcriptase inhibitor (NNRTI) - such as efavirenz or nevirapine - but found that it didn't work.
The study aims to assess resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. profiling and subsequent prescription patterns of patients on NNRTIs
Those who have virologically failed previous NNRTI treatment, or have resistance to one drug in the NNRTI class are examined further in the study.
Non-nucleoside Reverse Transcriptase Inhibitor Failure in a High HIV Caseload Australian Primary Care Practice
existing_drug – NNRTIs
June 2010 (This may be the proposed or expected start date for trials which have not yet started.)
1000 (The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.)
You may be eligible to participate in this trial if you meet the following criteria:
This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.
While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.
Before making the decision to participate in any clinical research, visit the NAPWA website for background information on participating in clinical research.
Contact NAPWA if you have any questions or comments about this trial.